View printer-friendly version |
« Back |
January 03, 2016 2:30 a.m. |
![]() |
Teva Announces Exercise of Underwriters’ Over-Allotment Option |
![]() |
![]() |
Teva intends to use the net proceeds from these offerings towards the
cash portion of the purchase price for its previously announced
acquisition of
The offerings were made pursuant to a prospectus and related prospectus
supplements that constitute a part of Teva’s shelf registration
statement filed with the
This press release is for informational purposes only and does not
constitute an offer to sell or the solicitation of an offer to buy any
security of Teva, nor will there be any sale of any such security in any
jurisdiction in which such offer, sale or solicitation would be
unlawful. The offerings may be made only by means of the applicable
prospectus supplement and accompanying base prospectus. In particular,
the offer and sale of the Mandatory Convertible Preferred Shares can
only be conducted outside of About Teva
Cautionary Notice Regarding Forward-Looking Statements
This release contains forward-looking statements, which express the
current beliefs and expectations of management and involve a number of
known and unknown risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products;
competition for our specialty products, especially Copaxone®
(including competition from orally-administered alternatives, as well as
from generic equivalents such as the recently launched View source version on businesswire.com: http://www.businesswire.com/news/home/20160102005007/en/ Source:
Teva Pharmaceutical Industries Ltd. |